THE CHEMOTHERAPY OF COLON-CANCER

被引:18
作者
CONNORS, TA [1 ]
DUNCAN, R [1 ]
KNOX, RJ [1 ]
机构
[1] CRC,CTR CANC THERAPEUT,CANC RES INST,SUTTON,SURREY,ENGLAND
关键词
COLON CANCER; CHEMOTHERAPY; ANTIBODY TARGETING; DRUG TARGETING; POLYMER TARGETING; PRODRUGS; PET SCANNING; VACCINES;
D O I
10.1016/0959-8049(95)00180-Q
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite extensive clinical trials, mortality from colon cancer has remained essentially unchanged since the 1950s. However, the increasing numbers of complete and partial responses seen in clinical trials suggest that colon cancer can be successfully treated by chemotherapy, but only if the antitumour selectivity can be increased by a substantial amount. This will be possible by the introduction of new drugs with more precise mechanisms of action, such as those acting specifically on signalling or cell cycle control pathways shown to be aberrant in colon cancer. Alternatively, the selectivity of present day agents may be increased considerably by the selective activation of prodrugs in tumours (ADEPT) or by targeting them to tumours using polymers. Other new approaches using vaccines or some form of gene therapy will potentiate present chemotherapy, while the introduction of positron emission tomography (PET) scanning will allow the rapid detection of agents with activity that would have been missed by conventional measurements of response.
引用
收藏
页码:1373 / 1378
页数:6
相关论文
共 30 条
[1]   THE 1ST BAGSHAWE LECTURE - TOWARDS GENERATING CYTO-TOXIC AGENTS AT CANCER SITES [J].
BAGSHAWE, KD .
BRITISH JOURNAL OF CANCER, 1989, 60 (03) :275-281
[2]  
CASSIDY J, 1989, BIOCHEM PHARMACOL, V38, P857
[3]   CURE OF MICE BEARING ADVANCED PLASMA CELL TUMOURS WITH ANILINE MUSTARD - RELATIONSHIP BETWEEN GLUCURONIDASE ACTIVITY AND TUMOUR SENSITIVITY [J].
CONNORS, TA ;
WHISSON, ME .
NATURE, 1966, 210 (5038) :866-&
[4]  
CROWELL PL, 1991, J BIOL CHEM, V266, P17679
[5]   CLINICAL OUTCOME OF COLORECTAL-CANCER PATIENTS TREATED WITH HUMAN MONOCLONAL ANTIIDIOTYPIC ANTIBODY [J].
DENTON, GWL ;
DURRANT, LG ;
HARDCASTLE, JD ;
AUSTIN, EB ;
SEWELL, HF ;
ROBINS, RA .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (01) :10-14
[6]   DRUG POLYMER CONJUGATES - POTENTIAL FOR IMPROVED CHEMOTHERAPY [J].
DUNCAN, R .
ANTI-CANCER DRUGS, 1992, 3 (03) :175-210
[7]   POLYMER CONJUGATES - PHARMACOKINETIC CONSIDERATIONS FOR DESIGN AND DEVELOPMENT [J].
DUNCAN, R ;
SPREAFICO, F .
CLINICAL PHARMACOKINETICS, 1994, 27 (04) :290-306
[8]   MACROMOLECULAR PRODRUGS FOR USE IN TARGETED CANCER-CHEMOTHERAPY - MELPHALAN COVALENTLY COUPLED TO N-(2-HYDROXYPROPYL) METHACRYLAMIDE COPOLYMERS [J].
DUNCAN, R ;
HUME, IC ;
YARDLEY, HJ ;
FLANAGAN, PA ;
ULBRICH, K ;
SUBR, V ;
STROHALM, J .
JOURNAL OF CONTROLLED RELEASE, 1991, 16 (1-2) :121-136
[9]   TARGETING OF N-(2-HYDROXYPROPYL)METHACRYLAMIDE CO-POLYMERS TO LIVER BY INCORPORATION OF GALACTOSE RESIDUES [J].
DUNCAN, R ;
KOPECEK, J ;
REJMANOVA, P ;
LLOYD, JB .
BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 755 (03) :518-521
[10]  
DUNCAN R, 1992, J CONTROL RELEASE, V19, P341